OTIMIZANDO O USO DO EMICIZUMABE EM PACIENTES COM HEMOFILIA A E INIBIDOR POR MEIO DO SOFTWARE CALIBRA
2023 · Hematology Transfusion and Cell Therapy · 0 citations
https://doi.org/10.1016/j.htct.2023.09.881
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
1
Citations
1
h-index
0
i10-index
AEMQ Liparizi is an academic researcher. The author has contributed to research in topics: Hemophilia Treatment and Research & Blood donation and transfusion practices & Atrial Fibrillation Management and Outcomes. The author has an h-index of 1, co-authored 8 publications.
https://doi.org/10.1016/j.htct.2023.09.881
https://doi.org/10.1016/j.htct.2023.09.894
https://doi.org/10.1016/j.htct.2023.09.880
https://doi.org/10.1016/j.htct.2024.09.959
Click to start Chat